Lentiviral Gene Therapy for p47 AR-CGD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Lentiviral Gene Therapy for p47 AR-CGD — Stella

Home/P47-Phox, Deficiency of/

View on ClinicalTrials.gov

Recruiting

Back to P47-Phox, Deficiency of trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United Kingdom

Great Ormond Street Hospital, London

Key details

Phase

Early testing / Safety & dosing

Sponsor

Great Ormond Street Hospital for Children NHS Foundation Trust

Enrollment target

~5 participants

Started

March 2023

Primary completion

April 2029

Age range

23 Months and older

Last updated May 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.